Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Polaris GroupTPE:6550 62 Equity-to-Asset is 0.62 as of Jun. 2026, which is 18% below its 10-year median of 0.76. GuruFocus rates TPE:6550 with a GF Score™ of 62/100 and a GF Value™ of NT$73.94 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,410 Biotechnology companies, Polaris Group ranks worse than 57.16% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Polaris Group's Total Stockholders Equity for the quarter that ended in Jun. 2026 was NT$4,540.90 Mil. Polaris Group's Total Assets for the quarter that ended in Jun. 2026 was NT$7,383.65 Mil.
Therefore, Polaris Group's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.62.
The historical rank and industry rank for Polaris Group's Equity-to-Asset or its related term are showing as below:
TPE:6550'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.11 Med: 0.76 Max: 0.94
Current: 0.62
During the past 13 years, the highest Equity to Asset Ratio of Polaris Group was 0.94. The lowest was 0.11. And the median was 0.76.
TPE:6550's Equity-to-Asset is ranked worse than 57.16% of 1410
companies
in the Biotechnology industry
Industry Median: 0.69
vs TPE:6550: 0.62
Polaris Group (TPE:6550) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Polaris Group Equity-to-Asset Related Terms
Polaris Group Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Polaris Group's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6550 vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Polaris Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polaris Group Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Polaris Group's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Polaris Group's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Polaris Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polaris Group (TPE:6550) has a Equity-to-Asset of 0.62 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Polaris Group and its competitors. This is 18% below median its historical median of 0.76. Over the past decade, Polaris Group's Equity-to-Asset has ranged from 0.11 to 0.94. According to the industry distribution chart, Polaris Group ranks #806 out of 1410 companies in the Biotechnology industry, placing it in the top 57.2%.
Is Polaris Group's Equity-to-Asset too high?
Polaris Group's current Equity-to-Asset of 0.62 is 18% below median its 10-year median of 0.76. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 0.94. The Biotechnology industry median Equity-to-Asset is 0.69. Polaris Group's value of 0.62 is 10.1% below this industry median. Based on the distribution chart, Polaris Group ranks #806 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Polaris Group has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Polaris Group's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Polaris Group ranks #806 out of 1410 companies for Equity-to-Asset. This places Polaris Group in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Polaris Group's value of 0.62 is 10.1% below this benchmark. Historically, Polaris Group's own Equity-to-Asset has ranged from 0.11 to 0.94 over the past decade. While the company's 10-year median is 0.76 vs. the industry median of 0.69, Polaris Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polaris Group's current Equity-to-Asset of 0.62 is 10.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Polaris Group and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polaris Group's current Equity-to-Asset is 0.62, which is 18% below median its own 10-year median of 0.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaris Group stock overvalued right now?
Based on GuruFocus' analysis, Polaris Group (TPE:6550) is currently considered Possible Value Trap. The stock's GF Value™ is NT$73.94, compared to a current price of NT$19.10 — trading 74.2% below its estimated fair value. The current Equity-to-Asset is 0.62, which is 18% below median its 10-year median of 0.76 and 10.1% below the Biotechnology industry median of 0.69. Polaris Group's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Polaris Group (TPE:6550), the current Equity-to-Asset is 0.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polaris Group (TPE:6550) Overvalued in 2026?
Based on GuruFocus' analysis, Polaris Group stock appears to be undervalued.
The current stock price of NT$19.10 is trading 74.2% below its estimated GF Value™ of NT$73.94.
GuruFocus considers Polaris Group to be Possible Value Trap.
Key valuation signals for TPE:6550:
Equity-to-Asset: 0.62 (18% below median its 10-year median of 0.76)
GF Value™: NT$73.94 vs. price of NT$19.10 (74.2% below fair value)
Industry Position: 10.1% below the Biotechnology median (#806 of 1410)
No single metric tells the full story. See the TPE:6550 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.
62GF Score
Get the complete analysis for TPE:6550
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6550 has been successfully added to your 
